|
|
Zhaosheng Lin
Head of Biomarkers
Pfizer
 Nadine Cohen Head of Pharmacogenomics
Johnson & Johnson
 Mitchell B. Friedman Director of Toxicology
Takeda Global R&D
 Malcolm Mitchell Medical Director, Clinical Pharmacology
Eli Lilly
 Dr Russell Weiner Group Director
Bristol-Myers Squibb
|
Conference:
Pre-conference workshop
19 Oct 9am - 5pm
Day 1
20 Oct 8.30am - 5:30pm
Day 2
21 Oct 8.30am - 5:30pm
Post-conference workshop
22 Oct 9am - 5pm
Venue: Boston, MA, United States
› Email a friend
› Add this to my calendar
|
|
|
 Dr Russell Weiner,
Group Director Bristol-Myers Squibb Russ Weiner is currently Executive Director of the Merck Clinical Development Lab. In this role he is responsible for clinical biomarker assay development, fit-for-purpose validation and sample analysis. Russ received his Ph.D. in Biochemistry from Albany Medical College and in 1993 joined the Bristol-Myers Squibb. During his tenure at BMS, Russ directed the Clinical Biomarker Development group combining the technologies of immunochemistry, LC/MS, molecular biology, molecular pathology and flow cytometry. Russ broadened his non-bioanalytical responsibilities to include Chairing the Immunology-Early Development Team. In this role Russ served as study director on over a dozen Phase I/II clinical studies and transitioned 5 compounds from discovery to IND submission and subsequent first-in-human studies. Prior to joining Merck, Russ directed the Biomarker and Bioanalytical Sciences group at Bristol-Myers Squibb. In this role he was responsible for discovery and regulated bioanalysis in support of PK, immunogencity of biologic therapeutics and biomarker assay development, validation and sample analysis. Russ is an active member of Applied Pharmaceutical Analysis (APA) and the American Association of Pharmaceutical Scientists (AAPS). He currently serves as the co-Chair/Chair of the 2010/11 APA meetings and has served as the Chair of the AAPS 2009 Annual Meeting and Chair of the AAPS Biotechnology Section. Appearing: Day Two, Thursday 21 October 2010 1.45pm Practical Considerations When Implementing a Fit-for-purpose Biomarker Assay Development Paradigm
- Practical examples of fit-for-purpose biomarker assays.
- Pros and cons of in-house assay development versus using an off the shelf kits
- Case Studies: issues encountered when using “for research only” kits.
- Case Studies: knowing what you need to measure- total-versus-free analyte
Dr Russell Weiner, Group Director,
Bristol-Myers Squibb |
|
|
|
|
|
Reserve an exhibition stand at the Exploratory Clinical Development World Americas exhibition - book early to ensure optimum stand placement!
| |
Reserve a stand
For details contact
Claire Conway on +44 (0) 207 608 7058 |
|
|
|
|
|
|
|
|
|
